- Home
- IPHA vs BGX Comparison
IPHA vs BGX Comparison
Compare IPHA & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IPHA | BGX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | United States |
| Employees | 174 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.1M | 135.2M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | IPHA | BGX |
|---|---|---|
| Price | $1.33 | $10.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | 19.0K | ★ 105.5K |
| Earning Date | 03-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $181.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $10.38 |
| 52 Week High | $2.63 | $12.65 |
Technical Indicators
Market Signals| Indicator | IPHA | BGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 47.89 |
| Support Level | $1.18 | $10.42 |
| Resistance Level | $1.88 | $11.92 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 65.54 | 61.40 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About BGX Blackstone Long Short Credit Income Fund
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The company's seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.